{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:52:02Z","timestamp":1791460322881,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yrtph.2026.106246","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:08:03Z","timestamp":1788970083000},"page":"106246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Applications of in vitro new approach methodologies (NAMs) in drug development: A scoping analysis of titles of nonclinical study reports submitted to the FDA"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2262-3307","authenticated-orcid":false,"given":"Yanning","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyna","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7623-7812","authenticated-orcid":false,"given":"Nakissa","family":"Sadrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.yrtph.2026.106246_bib1","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106246_bib2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.yrtph.2026.106246_bib3","article-title":"A CDER perspective: landscape of new approach methodologies (NAMs) submitted in drug development programs","author":"Dao","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106246_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun. Med."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106246_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41551-019-0498-9","article-title":"Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips","volume":"4","author":"Herland","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"5986","key":"10.1016\/j.yrtph.2026.106246_bib6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1126\/science.1188302","article-title":"Reconstituting organ-level lung functions on a chip","volume":"328","author":"Huh","year":"2010","journal-title":"Science"},{"issue":"159","key":"10.1016\/j.yrtph.2026.106246_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004249","article-title":"A human disease model of drug toxicity\u2013induced pulmonary edema in a lung-on-a-chip microdevice","volume":"4","author":"Huh","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yrtph.2026.106246_bib8","series-title":"M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals","year":"2010"},{"key":"10.1016\/j.yrtph.2026.106246_bib9","series-title":"Photosafety Evaluation of Pharmaceuticals S10","year":"2013"},{"issue":"517","key":"10.1016\/j.yrtph.2026.106246_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5516","article-title":"Reproducing human and cross-species drug toxicities using a Liver-Chip","volume":"11","author":"Jang","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106246_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103884","article-title":"Human iPSC-derived renal organoids engineered to report oxidative stress can predict drug-induced toxicity","volume":"25","author":"Lawrence","year":"2022","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.yrtph.2026.106246_bib12","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.yrtph.2026.106246_bib13","article-title":"Test No. 432: in vitro 3T3 NRU Phototoxicity Test","volume":"4","year":"2019"},{"key":"10.1016\/j.yrtph.2026.106246_bib14","article-title":"Test no. 492B: reconstructed Human Cornea-like Epithelium (RHCE) Test method for eye hazard identification","volume":"4","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106246_bib15","article-title":"Test No. 439: in vitro skin irritation: reconstructed Human Epidermis Test method","volume":"4","year":"2025"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106246_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41551-020-0539-4","article-title":"Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity","volume":"4","author":"Richards","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.yrtph.2026.106246_bib17","series-title":"Food and Drug Omnibus Reform Act of 2022 (FDORA)","first-page":"2022","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106246_bib18","volume":"3.0","year":"2026","journal-title":"FDA Modernization Act"},{"key":"10.1016\/j.yrtph.2026.106246_bib19","series-title":"Roadmap to Reducing Animal Testing in Preclinical Safety Studies","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106246_bib20","series-title":"General Considerations for the Use of New Approach Methodologies in Drug Development: Draft Guidance for Industry","year":"2026"},{"key":"10.1016\/j.yrtph.2026.106246_bib21","series-title":"Reducing Animal Testing in Nonclinical Studies: Year One Progress and the Path Forward","year":"2026"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:04:52Z","timestamp":1791457492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"alternative-id":["S0273230026002199"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106246","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applications of in vitro new approach methodologies (NAMs) in drug development: A scoping analysis of titles of nonclinical study reports submitted to the FDA","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106246"}}